BiotechTube

SENS-401 + SENS-401

Phase 2/3Completed
0 watching 0 views this week⚡ Active
57
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Severe Sudden Sensorineural Hearing Loss

Conditions

Severe Sudden Sensorineural Hearing Loss

Trial Timeline

Feb 15, 2019 → Jan 12, 2022

NCT ID
NCT03603314

About SENS-401 + SENS-401

SENS-401 + SENS-401 is a phase 2/3 stage product being developed by Sensorion for Severe Sudden Sensorineural Hearing Loss. The current trial status is completed. This product is registered under clinical trial identifier NCT03603314. Target conditions include Severe Sudden Sensorineural Hearing Loss.

Hype Score Breakdown

Clinical
22
Activity
15
Company
2
Novelty
7
Community
8

Clinical Trials (1)

NCT IDPhaseStatus
NCT03603314Phase 2/3Completed

Competing Products

20 competing products in Severe Sudden Sensorineural Hearing Loss

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
80
Drotrecogin alfa (activated)Eli LillyPhase 2
52
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
77
CT-P17 + EU-approved HumiraCelltrionPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
CS-3150Daiichi SankyoPhase 3
77
tacrolimusAstellas PharmaApproved
85
enzalutamideAstellas PharmaPhase 1
33
Isavuconazonium Injection [Cresemba] + PlaceboAstellas PharmaPhase 3
77
AlefaceptAstellas PharmaApproved
85
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
52
Tildrakizumab 100 mg + PlaceboSun PharmaceuticalPhase 3
77
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + PlaceboSun PharmaceuticalPhase 2/3
65
CefiderocolShionogiApproved
85
eritoran tetrasodium + PlaceboEisaiPhase 3
77
Donepezil HClEisaiApproved
85
Donepezil Hydrochloride (Aricept)EisaiApproved
85
KHK4827 + PlaceboKyowa KirinPhase 3
77

Other Products from Sensorion

SENS-401 (R-Azasetron Besylate)Phase 2
44
SENS-111 100mg + SENS-111 200mg + Placebo Oral TabletPhase 2
44
SENS-401 (R-Azasetron Besylate)Phase 2
44
SENS-218Phase 1
25
SENS-401 + PlaceboPhase 1
25